SLAMF9: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of SLAMF9. The page also collects GeneMedi's different modalities and formats products for SLAMF9 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the SLAMF9 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Introcelluar Protein.

This gene encodes a member of the signaling lymphocytic activation molecule family. The encoded protein is a cell surface molecule that consists of two extracellular immunoglobulin domains, a transmembrane domain and a short cytoplasmic tail that lacks the signal transduction motifs found in other family members. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Apr 2009]

Target IDGM-IP1642
Target NameSLAMF9
Gene ID89886,98365,289235,719554,100684400,101091842,507627,100630053
Gene Symbol and Synonyms2310026I04Rik,CD2F-10,CD2F10,CD84-H1,CD84H1,SF2001,SLAMF9
Uniprot AccessionQ96A28
Uniprot Entry NameSLAF9_HUMAN
Protein Sub-locationIntrocelluar Protein
Category
DiseaseN/A
Gene EnsemblENSG00000162723
Target ClassificationN/A


Pre-made anti-SLAMF9 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-SLAMF9 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-SLAMF9 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-SLAMF9 monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabDetail



Recombinant multi-species SLAF9/ SLAMF9/ CD2F-10 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SLAMF9 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
SLAMF9 proteinHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellDetail